Videos

Non-Driver NSCLC: Practice Considerations

Ghassan K. Abou-Alfa, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses results of the CELESTIAL trial. The results were clinically and statistically significant, Abou-Alfa notes. 

Clinical Decisions in Non-Driver NSCLC

Mark G. Kris, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the recent FDA approval of durvalumab (Imfinzi) for the treatment of patients with locally advanced, unresectable stage III non–small cell lung cancer.

David M. Nanus, MD, chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine, discusses the use of immunotherapy in the community setting. He also gives advice to community oncologists that are using these treatments in their practice.&nbsp;<br /> &nbsp;

Colorectal Cancer: Managing Recurrent Disease

Jennifer Litton, MD, associate professor in the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses the role of biosimilars in the treatment of breast cancer.

Robert &quot;Bo&quot; Gamble, director of Strategic Practice Initiatives, Community Oncology Alliance (COA), discusses some of the exciting topics that will be covered during the upcoming 2018 Community Oncology Conference.&nbsp;

James Hamrick, MD, senior medical director, Flatiron Health, discusses how clinical trials can be improved in the community setting during the&nbsp;ACCC 44th Annual Meeting &amp; Cancer Center Business Summit.

Experts in the gynecologic oncology field share their key takeaways from the 2018 Society of Gynecologic Oncology (SGO) Annual Meeting on Women&rsquo;s Cancer, held at the Hyatt Regency Resort &amp; Convention Center in New Orleans, Louisiana, from March 24 to 27, 2018.

Miguel-Angel Perales, MD, deputy chief of Adult Bone Marrow Transplant Service at Memorial Sloan Kettering Cancer Center, discusses what experts are expecting to change in the treatment landscape of non-Hodgkin&rsquo;s lymphoma in the next year. Perales says by the end of 2018, there may be 3 CAR T-cell therapies approved for the treatment of non-Hodgkin&rsquo;s lymphoma.

Jaron Mark, MD, gynecologic oncology fellow at Roswell Park Comprehensive Cancer Center, discusses findings from a restrictive protocol that limited the number of opioids prescribed after gynecologic surgeries. Patients looked at in this trial had undergone ambulatory or minimally invasive procedures.&nbsp;

Akihito Kawazoe, MD, discussed the safety and efficacy results of the phase I/II SCOOP trial of napabucasin plus pembrolizumab for treatment of patients with metastatic colorectal cancer.